2026 NPPES data Endocrinology, Diabetes & Metabolism Physician NPI 1164414652 M.D.
Verify on CMS →

RAYMOND FINK, M.D.

Endocrinology, Diabetes & Metabolism Physician in LA MESA, California. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
228
Medicare Part D claims · 114 beneficiaries · Endocrinology, Diabetes & Metabolism Physician avg: 3K
Generic prescribing
51%
generic claims · 49% brand-name · higher generic rates reduce patient out-of-pocket costs

What the federal data shows

RAYMOND FINK, M.D. filed 228 Medicare Part D claims in 2023 as a Endocrinology, Diabetes & Metabolism Physician in LA MESA, California, prescribing 51% generic.

228
Part D claims, 2023
51%
generic prescribing

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

RAYMOND FINK, M.D.'s Medicare Part D volume vs every U.S. prescriber

Total Medicare Part D claims, 2023 — across all CMS prescribers nationally

228 49th percentile higher than 49% of 1,370,886 prescribers

0–200: 670,926 prescribers (49%). Below this entry. 200–400: 182,923 prescribers (13%). This entry sits in this band. 400–600: 90,619 prescribers (7%). Above this entry. 600–800: 56,224 prescribers (4%). Above this entry. 800–1,000: 40,919 prescribers (3%). Above this entry. 1,000–1,200: 31,827 prescribers (2%). Above this entry. 1,200–1,400: 26,224 prescribers (2%). Above this entry. 1,400–1,600: 21,710 prescribers (2%). Above this entry. 1,600–1,800: 19,072 prescribers (1%). Above this entry. 1,800–2,000: 16,451 prescribers (1%). Above this entry. 2,000–2,200: 213,991 prescribers (16%). Above this entry. This provider 0 2K+ every Part D prescriber (claims/yr), bucketed by value

Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Medicare Part D Prescriber Public Use File · 2023

Board-eligible specialty (heuristic — not verified)

RAYMOND FINK, M.D. practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about RAYMOND FINK, M.D.?

Quality data not reported

NPI registry status

Active

Issued 08/19/2005

NPI 1164414652

Primary specialty

Endocrinology, Diabetes & Metabolism Physician

Mid-sized

7,852 US NPIs in this specialty

Medicare Part D claims

228 91% vs specialty avg

2023 prescription claims

Specialty avg: 2,639

Specialty distribution in California

How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among California providers

California providers

Endocrinology, Diabetes & Metabolism Physician share within California

1. Endocrinology, Diabetes & Metabolism Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Endocrinology, Diabetes & Metabolism Physician share within California

Specialty board-certification context

Estimated specialty board-certified rate — Endocrinology, Diabetes & Metabolism Physician (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Endocrinology, Diabetes & Metabolism Physician ABMS/AOA estimate

Est. board-certified rate (Endocrinology, Diabetes & Metabolism Physician) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Endocrinology, Diabetes & Metabolism Physician) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

RAYMOND FINK, M.D. appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding M.D. credentials at 8851 CENTER DR, LA MESA, CA, 91942, with a listed phone of (619) 463-1293. NPI 1164414652 was issued on 08/19/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what FINK most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 228 prescription claims written by this provider, covering 114 Medicare beneficiaries and totaling roughly $118K in drug spend, split 49% brand-name and 51% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

8851 CENTER DR
LA MESA, CA 91942

Provider Details

NPI 1164414652
Specialty Endocrinology, Diabetes & Metabolism Physician
Credentials M.D.
Gender Male
NPI Issued 08/19/2005

License & disciplinary context — California MBC 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 — they are NOT specific to RAYMOND FINK, M.D.. To verify RAYMOND FINK, M.D.'s current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases

MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Above average

RAYMOND FINK, M.D. — brand share 49.0%
Specialty average (est.)

49% brand-name claims vs 51% generic, on 228 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

228
Total Claims
$118K
Total Drug Cost
114
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
526
Total Day Supply
15,557
Brand vs Generic
49% brand / 51% generic
Brand Drug Cost
$115K
Generic Drug Cost
$3K

Patient Demographics

Average Patient Age
75.1 years
Avg HCC Risk Score
1.73
Gender Split
47% female / 53% male
Age Distribution
<65: 12, 65-74: 42, 75-84: 43, 85+: 17

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What RAYMOND FINK, M.D. prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Humalog Kwikpen U-100
Insulin Lispro
19
Levothyroxine Sodium
18
Farxiga
Dapagliflozin Propanediol
14
Atorvastatin Calcium
13
Tresiba Flextouch U-200
Insulin Degludec
12
Jardiance
Empagliflozin
11
Losartan Potassium
11
Rosuvastatin Calcium
11

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Endocrinology, Diabetes & Metabolism Physician Overview

How RAYMOND FINK, M.D. fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.

7,852
Endocrinology, Diabetes & Metabolism Physician Providers in US
54
States with Endocrinology, Diabetes & Metabolism Physician
2,639
Avg Claims per Provider

RAYMOND FINK, M.D.'s 228 claims are below the specialty average of 2,639.

Nearby Endocrinology, Diabetes & Metabolism Physician Providers in California

Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as FINK.

Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is RAYMOND FINK, M.D.'s specialty?
RAYMOND FINK, M.D. specializes in Endocrinology, Diabetes & Metabolism Physician and practices in LA MESA, California. Credentials: M.D..
How much does RAYMOND FINK, M.D. prescribe under Medicare Part D?
In 2023, RAYMOND FINK, M.D. wrote 228 Medicare Part D claims totaling $118K in drug costs for 114 beneficiaries.
Where is RAYMOND FINK, M.D. located?
RAYMOND FINK, M.D. is located at 8851 CENTER DR, LA MESA, CA, 91942. Phone: (619) 463-1293.
What is RAYMOND FINK, M.D.'s NPI number?
RAYMOND FINK, M.D.'s National Provider Identifier (NPI) is 1164414652, issued on 08/19/2005.
Does RAYMOND FINK, M.D. prescribe more brand-name or generic drugs?
RAYMOND FINK, M.D.'s prescribing is 49% brand-name and 51% generic drugs by claim count, with $115K in brand drug costs.
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US?
There are 7,852 Endocrinology, Diabetes & Metabolism Physician providers across 54 states in the US. The average Endocrinology, Diabetes & Metabolism Physician provider writes 2,639 Medicare Part D claims per year.
What drugs does RAYMOND FINK, M.D. prescribe most often?
Based on 2023 Medicare Part D data, RAYMOND FINK, M.D.'s most frequently prescribed drugs include Humalog Kwikpen U-100, Levothyroxine Sodium, Farxiga. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does RAYMOND FINK, M.D. accept Medicare?
RAYMOND FINK, M.D. appears in CMS Medicare data with 228 Part D claims and 114 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify RAYMOND FINK, M.D.'s credentials?
RAYMOND FINK, M.D.'s NPI is 1164414652 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology